Genomics (TXG) closed the last trading session at $8.86, gaining 7.1% over the past four weeks, but there could be plenty of ...

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings ...

Ark Invest made significant trades in TSLA, TXG, NTLA, DDD, and ADPT. Purchase of TXG and NTLA from ARKG and ARKK funds, and sale of TSLA, DDD, and ADPT from various funds.

10x Genomics, Inc. (TXG) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings. Skip to content Home page ...

10x Genomics (TXG) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.33 per share a year ago. These figures are ...

Investors in 10x Genomics Inc (Symbol: TXG) saw new options become available today, for the January 2024 expiration. One of the key data points that goes into the price an option buyer is willing ...

I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption ...

10x Genomics (TXG) closed the last trading session at $8.86, gaining 7.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...